Medication info
Klerosh 10 mg (Rosuvastatin Calcium)

Klerosh 10 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Sama Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/alu-alu X3)
Approval status
Active

MFDS item code 201001011 · Notified 2010.01.28 · Insurance code 645702150

Summary

Main use
Treats dyslipidemia, slows the progression of atherosclerosis, and prevents cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 mg daily. 3. Older adults : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medication to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race : Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be individualized for each patient according to the recommended treatment goals. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
Sama Pharmaceutical Co., Ltd.

Efficacy & effects

Treats dyslipidemia, slows the progression of atherosclerosis, and prevents cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed-type hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • early coronary artery disease family history
View approved original text

This medication is used as an adjunct when diet and exercise alone do not adequately control primary hypercholesterolemia and mixed hyperlipidemia. It is also used as an adjunct to diet or other therapies in patients with homozygous familial hypercholesterolemia. It effectively lowers total cholesterol and LDL-C levels in hypercholesterolemic patients, delaying the progression of atherosclerosis. It is also used as an adjunct to diet in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, helping those with high blood LDL-C levels. It plays a role in assisting dietary therapy for primary dysbetalipoproteinemia patients. Furthermore, in men over 50 years and women over 60 years with risk factors for cardiovascular disease, it helps reduce the risk of cardiovascular diseases such as stroke and myocardial infarction. This medication is used for hypercholesterolemia and reduction of cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 mg daily. 3. Older adults : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medication to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race : Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be individualized for each patient according to the recommended treatment goals. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Precautions

This medication should not be used in certain patients. For example, those who are allergic to this medication, have severe liver disease, have muscle disorders, or have severely impaired kidney function may be at risk if they take this medication. Pregnant or nursing women, or fertile women not using proper contraception should also not take this medication. High-dose use is particularly prohibited in patients at high risk for muscle disorders. Additionally, this medication contains lactose and should not be administered to patients with lactose intolerance or related genetic conditions. It is important to periodically check liver function and muscle condition while taking this medication. Patients who consume large amounts of alcohol or have a history of liver disease require caution, and those with conditions like hypothyroidism or nephrotic syndrome must treat those conditions first. If symptoms such as myalgia, muscle weakness, or cramps appear, medical personnel must be informed immediately, and this medication may need to be discontinued if necessary. This medication may interact with other drugs, so patients should inform their doctor or pharmacist of any other medications they are taking. In particular, concurrent use with ciclosporin, fibrate drugs, or certain antibiotics and antifungals may increase the risk of muscle injury. Pregnant or nursing women should not use this medication, and fertile women must ensure proper contraception. There are no specific antidotes for overdose, so monitoring should be conducted through symptomatic treatment and tests for liver function and muscle enzymes. Lastly, this medication may cause dizziness, so caution is advised when driving or operating machinery.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, drug eruptions resembling psoriasis, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, discomfort in the chest, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture and kept in a cool place below 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/alu-alu X3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.